Posted on February 7, 2008 by jrowley
Geron yesterday announced the issuance of US patent #7,326,572, helping to extend their patent protection around their embryonic stem (ES) cell platform technology in the area of treating type 1 diabetes. Currently, Geron owns an exclusive license from the Wisconsin Alumni Research Foundation (WARF) for James Tomson’s original ES patents. This license allows [...]
Filed under: Embyonic Stem Cells, Geron, Intellectual Property, Novocell, Regenerative Medicine, Type 1 diabetes | Tagged: culture conditions, embryonic germ cells, endoderm, patent protection | No Comments »
Posted on January 4, 2008 by jrowley
I have recently signed up for the StemCellPatents.com weekly newsletter, and it is great to keep updated on all the patents that get issued in regenerative medicine. In the most recent newletter, they reported on two patents that issued last week that strengthen Celgene’s patent estate in adult stem cells. Celgene got into the stem [...]
Filed under: Biomaterials, Celgene, Intellectual Property, Regenerative Medicine, adult stem cell, placenta stem cells, stem cells | Tagged: acquisition, Anthrogenesis, Celgene, patent strategy, placenta stem cells | 1 Comment »
Posted on December 7, 2007 by jrowley
The author of CELLWISE, one of the newer bio-Blogs out there, asked a question related to the Patent Reform Act of 2007 in a comment on the Pfizer post. He asked:
The article that is cited is right; our patent system is not optimized for today’s innovations or our different industries. The patent office is [...]
Filed under: Big Pharma, Innovation, Intellectual Property, Regenerative Medicine | Tagged: convergent technologies, Innovation, Patent Reform Act, patent thicket, Regenerative Medicine | No Comments »
Posted on November 26, 2007 by jrowley
CellCyte Genetics Corporation recently announced that US Patent No 7,282,222 was issued, a patent which they have exclusive rights to. The press release states that the patent covers unique methods and compositions “to deliver and direct stem cells to target organs in the body”, including cardiac tissue.
The focus of the patent addresses cell retention at [...]
Filed under: Clinical Trials, Intellectual Property, Regenerative Medicine, cardiac regeneration, cell delivery, stem cells | 1 Comment »
